Bailard, Inc. Jounce Therapeutics, Inc. Transaction History

Bailard, Inc.

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 08, 2023	BUY	$0.9 - $1.85 $81,180 - $166,870	90,200 New	90,200 $166,000
Q1 2022 Apr 25, 2022	SELL	$6.01 - $8.54 $192,031 - $272,870	-31,952 Closed	0 $0
Q2 2021 Aug 13, 2021	BUY	$6.58 - $10.66 $101,332 - $164,164	15,400 Added 93.04%	31,952 $217,000
Q1 2021 May 13, 2021	BUY	$6.73 - $13.87 $6,730 - $13,870	1,000 Added 6.43%	16,552 $170,000
Q4 2020 Feb 03, 2021	BUY	$6.37 - $10.33 $5,733 - $9,297	900 Added 6.14%	15,552 $109,000
Q4 2019 Jan 31, 2020	SELL	$2.81 - $9.21 $22,895 - $75,043	-8,148 Reduced 35.74%	14,652 $128,000
Q2 2019 Jul 26, 2019	BUY	$4.3 - $6.73 $34,400 - $53,840	8,000 Added 54.05%	22,800 $113,000
Q1 2019 Apr 24, 2019	BUY	$3.43 - $6.87 $50,764 - $101,676	14,800 New	14,800 $92,000

720K

Ticker JNCE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 51,694,200
Description
Jounce Therapeutics, Inc., a clinical-stage immunotherapy company, develops therapies for the treatment of cancer. The company develops vopratelimab, a clinical-stage monoclonal antibody, which is in Phase II clinical trial that binds to and activates the Inducible T cell CO-Stimulator, a protein on the surface of T cells found in various solid ...

Get notified when there are updates to the investment portfolio of Bailard, Inc., based on Form 13F filings with the SEC.

Stay updated on Bailard, Inc. with notifications on news.